Powered by IST's

Vectura to present at JP Morgan Conference

RNS

RNS Number : 5910B
Vectura Group plc
09 January 2015




Vectura Group plc


Vectura to present at the 33rd Annual J.P. Morgan Healthcare Conference, San Francisco

Chippenham, UK - 9 January 2015: Vectura Group plc ("Vectura"; LSE: VEC) announces today that it is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, 14 January 2014, at 4:30pm PST (12.30am 15 January GMT). The conference runs from 11-15 January 2015, at the Westin St. Francis Hotel in San Francisco, CA.

The presentation will be webcast live and can be reached from Vectura's website at http://www.vectura.com/investors/reports-presentations/2015.aspx. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software. A PDF of the presentation will also be available on Vectura's website at the same time.

-Ends-


Enquiries

Vectura Group plc
+44 (0)1249 667700
Karl Keegan, Chief Corporate Development Officer
Fleur Wood, Corporate Investor Relations



FTI Consulting
+44 (0)20 3727 1000
Ben Atwell / John Dineen / Ulla Lundhus

6 Jan 2015 Vectura Group PLC VEC JP Morgan Cazenove Overweight 142.38 144.75 - - Reiterates

NDA acceptance for QVA149 and NVA237
RNS
RNS Number : 6561G
Vectura Group plc
05 March 2015



Vectura Group plc



US FDA filing acceptance of NDAs for QVA149 and NVA237



Chippenham, UK - 5th March 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), confirms that Novartis' New Drug Applications (NDAs) for QVA149 and NVA237 for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) have been accepted for review by the US Food and Drug Administration (FDA). The filings were submitted by Novartis in Q4 2014. The acceptances trigger milestone payments to Vectura of $12.5m and $7.5m respectively.

-Ends-

A moderately good start to the year and climbing Sp has been lost after they ann a problem with major drugs co SKB ( DYOR )...it seems previous deals have been rather poor, with VEC getting rather little for "better" powders. Now they appear to have the inhaler/delivery improved further. . . you'd expect that would mean they'd share the profits - but it seems there is an issue and SKB have the upper hand ( Unless VEC can find ANOther to distribute the product . . . makes me wonder if BTG Sales force couldn't do this as they should by now have the warehousing ).
One wonders if the income won't dip in the short-term meaning there will be a cash-call - Oh dear.
Their products appear to be good-enough against existing puffers . . . . but to get the Market excited, I think they need to make it far clearer how these differ and why one model is better-suited, compared with another they make . . .otherwise it looks like clutter, to my mind.
8 Sept 2016...sp ~150p
EDIT (24April2017)-sp ~150p nothing worthwhile to report, I guess.
EDIT(20Oct2018)-oh dear sp 70p ish.... mighty fallen... anyone?
EDIT (25NoV2018)- Seems VEC's sp was hardly knocked with the failure of asthma-trial . . . you'd think just giving a puff to someone with asthma would show if it worked - if not, then move-on. Why put money into Trials if it didn't hold great promise?